John J. Kirby

Chief Financial Officer

Idera Pharmaceuticals, Inc.Verrica Pharmaceuticals Inc.

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 1 buy · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 1 buy · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (3 ops.)

€40k

▼ Sales (0 ops.)

—

Latest filing published 18 Aug 2026 for Verrica Pharmaceuticals Inc., €21k. Read the official filing

Filing timeline

BuySale

John J. Kirby

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-16.7%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

John J. Kirby: trading record in brief

This profile gathers the share dealings of John J. Kirby across 2 companies, led by Verrica Pharmaceuticals Inc. and Idera Pharmaceuticals, Inc. Over a trading history stretching from 17 December 2021 to 18 August 2026, the count stands at 6 filings.

No open-market sale appears; the market trades are 3 purchases worth €40k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 share grants. So far in 2026, the count stands at 1 purchase and no sales.

The median purchase comes to €13k. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 18 August 2026: an open-market purchase of €21k, in Verrica Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.